DeepMed Research

Poseida Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2014-01-01

Employees: 330

Market Cap: $272.9M

Website: http://www.poseida.com

Introduction: Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.

Clinical Trials

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Phase 1

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
DLBCL - Diffuse Large B Cell Lymphoma
DLBCL Arising From Follicular Lymphoma
DLBCL, Diffused Large B Cell Lymphoma
DLBCL NOS
High-grade B-cell Lymphoma
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
DLBCL
Transformed Follicular Lymphoma (tFL)
Follicular Lymphoma Grade 3B

Interventions: Biological: P-CD19CD20-ALLO1
Drug: Rimiducid

First Posted Date: 2023-08-28

Last Posted Date: 2025-05-13

Lead Sponsor: Poseida Therapeutics, Inc.

Target Recruit Count: 120

Registration Number: NCT06014762

Locations: 🇺🇸
Our Lady of the Lake Hospital, Baton Rouge, Louisiana, United States
🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States

and more 7 locations

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects with Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Breast Cancer
Non Small Cell Lung Cancer
Colorectal Cancer
Pancreatic Cancer
Nasopharyngeal Cancer
Ovarian Cancer
Head and Neck Squamous Cell Carcinoma
Renal Cell Carcinoma
Gastric Cancer

Interventions: Biological: P-MUC1C-ALLO1 CAR-T cells
Drug: Rimiducid

First Posted Date: 2022-02-14

Last Posted Date: 2025-03-10

Lead Sponsor: Poseida Therapeutics, Inc.

Target Recruit Count: 100

Registration Number: NCT05239143

Locations: 🇺🇸
University of California, Irvine Medical Center, Irvine, California, United States
🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of California, San Diego, San Diego, California, United States

and more 11 locations

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Biological: P-BCMA-ALLO1 CAR-T cells
Drug: Rimiducid

First Posted Date: 2021-07-14

Last Posted Date: 2025-05-14

Lead Sponsor: Poseida Therapeutics, Inc.

Target Recruit Count: 231

Registration Number: NCT04960579

Locations: 🇺🇸
Blood Marrow and Transplant Group of Georgia, Atlanta, Georgia, United States
🇺🇸
City of Hope, Chicago, Illinois, United States
🇺🇸
University of California San Diego, San Diego, California, United States

and more 17 locations

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Phase 1

Terminated

Conditions: Acinic Cell Tumor
Neoplasms by Histologic Type
Neoplasms, Prostate
Neoplasms
Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Prostatic Neoplasms, Castration-Resistant
Genital Neoplasms, Male
Prostatic Neoplasms
Urogenital Neoplasms

Interventions: Biological: P-PSMA-101 CAR-T cells
Drug: Rimiducid

First Posted Date: 2020-01-31

Last Posted Date: 2025-02-17

Lead Sponsor: Poseida Therapeutics, Inc.

Target Recruit Count: 40

Registration Number: NCT04249947

Locations: 🇺🇸
University of California San Diego, San Diego, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 7 locations

Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Rimiducid may be administered as indicated

First Posted Date: 2018-11-14

Last Posted Date: 2025-01-20

Lead Sponsor: Poseida Therapeutics, Inc.

Target Recruit Count: 100

Registration Number: NCT03741127

Locations: 🇺🇸
Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 10 locations

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Biological: P-BCMA-101 CAR-T cells
Drug: Rimiducid

First Posted Date: 2017-09-20

Last Posted Date: 2024-03-28

Lead Sponsor: Poseida Therapeutics, Inc.

Target Recruit Count: 105

Registration Number: NCT03288493

Locations: 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸
University of California San Diego, San Diego, California, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 13 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy